The cannabis company Dancann Pharma states in a New Year update that the company’s future strategy largely depends on a possible sale of the BP1 production facility. According to Chairman of the Board Carsten Trads, constructive talks are underway with several interested parties about selling the GMP-certified factory. Dancann Pharma continues to deliver to Stenocare during the first quarter. After the first quarter, Stenocare will handle the deliveries themselves. Dancann Pharma has sold shares in Stenocare to manage among smaller creditors. Dancann Pharma will delist the share from Spotlight.